Loading clinical trials...
Loading clinical trials...
A Phase 1, Multicenter, Open-label Study to Investigate the Safety and Biodistribution of a Single Intrathecal Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (The ASCEND Study)
Conditions
Interventions
INS1201
Locations
9
United States
USA012
Little Rock, Arkansas, United States
USA010
Davis, California, United States
USA002
Palo Alto, California, United States
USA005
San Diego, California, United States
Rare Disease Research (USA004)
Atlanta, Georgia, United States
USA008
Rochester, New York, United States
Start Date
July 22, 2025
Primary Completion Date
January 31, 2028
Completion Date
March 31, 2028
Last Updated
April 20, 2026
NCT06839469
NCT07037862
NCT07160634
NCT06450639
NCT05016908
NCT07129954
Lead Sponsor
Insmed Gene Therapy LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions